high mobility group box 1 pseudogene 9Genealiases: HMG1L9 · HMGB1L9
Q-omics provides the consensus-scored HMGB1P9 profile across patient tissues and cancer cell-line models. HMGB1P9 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, HMGB1P9 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, HMGB1P9 RNA expression shows 6,127 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight HNSC, and BRCA as cancer lineages where HMGB1P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGB1P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGB1P9 survival associations across molecular data types. HMGB1P9 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGB1P9 RNA expression–survival associations across cancer types. High HMGB1P9 expression shows unfavorable associations in KIRC, MESO, DLBC and BRCA, but favorable associations in HNSC and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for HMGB1P9 RNA expression.
This table summarizes HMGB1P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for HMGB1P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGB1P9 shows lower tumor expression in THCA and higher tumor expression in BRCA, STAD, HNSC and LUSC. The BRCA box plot shows higher HMGB1P9 RNA expression in tumor versus normal tissue (log2 FC = +0.025, t-test p = .043).
This table shows molecular features associated with HMGB1P9 in patient tissues and cancer cell lines. In patient samples, HMGB1P9 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
